UNSPSC 51314381: Pseudoephedrine/triprolidine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE501. This VA Drug Class (RE501) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT.

UNSPSC 51314381 Pseudoephedrine/triprolidine, a Commodity code, shows minimal alignment between its nominal scope and recent state and local procurement activity. The code appears in the source tagged to three solicitations, but only one — Seminole County, Florida's IFB for naloxone and drug deactivation systems — names a product remotely related to the code's pharmaceutical focus. The other two opportunities, the Texas Health and Human Services Commission's RFI for direct-to-manufacturer prescription programs and the Minnesota Multistate Cooperative Purchasing Alliance's RFP for generic multi-source pharmaceuticals and OTC products, involve broad pharmaceutical procurement mechanisms that do not target pseudoephedrine or triprolidine specifically. State and local governments appear to use this code inconsistently or tag opportunities under it when the actual procurement spans much wider pharmaceutical categories.

Issuing bodies include county health departments (Seminole County), state health and human services agencies (Texas HHS Commission), and multistate cooperative purchasing entities (MMCAP, serving Minnesota, Oregon, and other participating jurisdictions). Recent activity spans Florida, Texas, and the Upper Midwest through MMCAP's regional footprint. The Seminole County opportunity (IFB 60459723LAS, response due July 26, 2023) sought 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries; the Texas RFI (HHS0017013, posted April 3, 2026) gathered market intelligence on direct-to-manufacturer prescription contracting; and the MMCAP RFP (S1070000015802, due March 26, 2026) established multi-contract vehicles for generic pharmaceuticals and OTC products across state and local health systems. Actual procurement under the pseudoephedrine/triprolidine code does not appear to drive material activity — the opportunities tagged to it address naloxone, broad-based pharmacy benefit programs, and generic pharmaceutical distribution rather than the specific active ingredients the code names.